Seagen Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David R. Epstein
- Full Time Employees
- 3,256
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21823 30th Drive SE Bothell WA United States of America 98021
- IPO Date
- Mar 9, 2001
- CIK
- 0001060736
- Website
- seagen.com
- Similar Companies
- Business
- Seagen Inc. is a biotechnology company that discovers, develops, and commercializes monoclonal antibody-based therapies, primarily antibody-drug conjugates (ADCs), for the treatment of cancer. The company offers ADCETRIS (brentuximab vedotin) for Hodgkin lymphoma and systemic anaplastic large cell lymphoma; PADCEV (enfortumab vedotin-ejfv) for urothelial cancer; TIVDAK (tisotumab vedotin-tftv) for cervical cancer; and TUKYSA (tucatinib) for HER2-positive metastatic breast cancer and colorectal cancer; along with a pipeline of investigational ADCs and immuno-oncology agents targeting various solid tumors and hematologic malignancies. Seagen operates globally, with products approved in more than 65 countries including the United States, Canada, Japan, and European Union members, and serves pharmaceutical partners through ADC technology licensing and co-development agreements with companies such as Takeda, Astellas, and Genmab. Founded in 1997 as Seattle Genetics and renamed Seagen in 2020, the company is headquartered in Bothell, Washington. In December 2023, Pfizer Inc. completed its $43 billion acquisition of Seagen, integrating its ADC portfolio and pipeline into Pfizer's oncology division to double the combined oncology programs to 60 and accelerate development of next-generation cancer therapies. This strategic transaction, one of the largest in biopharma history, positions Pfizer to leverage Seagen's proprietary ADC technology for enhanced targeted treatments while contributing anticipated revenues of $3.1 billion in 2024 rising to $10 billion by 2030 from Seagen's products. Seagen's operations now support Pfizer's focus on oncology across breast, genitourinary, hematologic, and other cancers, with ongoing clinical trials expanding ADC applications.
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
President Trump demands drugmakers slash prices within 60 days
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
Pfizer: Seagen Acquisition Starting To Bear Fruit
Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition
Cramer names biopharma companies to watch as industry mergers start to pile up
5 Biotech Acquisition Targets To Accumulate In 2024
Pfizer Completes Acquisition of Seagen
Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen
8 Tax-Loss Sell Alerts For December
Pfizer to close Seagen acquisition after donating cancer drug rights
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
Pfizer expects to close Seagen deal on Thursday, will create a new oncology division to incorporate company
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag